Novel Therapies: Using GLP-1 Receptor Agonists in Cardiorenal Metabolic Syndrome [truly acv keto gummies reviews]

Novel Therapies: Using GLP-1 Receptor Agonists in Cardiorenal Metabolic Syndrome [truly acv keto gummies reviews]

| 1h 28m 28s | Video has closed captioning.

Join Drs Nihar Desai and Matthew Cavender as they discuss the history, studies, and implementation of GLP-1 receptor agonists for people with cardiorenal metabolic syndrome. Relevant disclosures can be found with the episode show notes on Medscape The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Glucagon-Like Peptide-1 Receptor Agonists Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death From Cardiovascular Causes Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; Availability Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes Effects of Oral Semaglutide on Cardiovascular Outcomes in Individuals With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: Design and Baseline Characteristics of SOUL, a Randomized Trial Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes Heart Failure With Preserved Ejection Fraction (HFpEF) Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial Semaglutide Versus Placebo in People With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF DM Randomised Trials Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial